arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Sagimet Biosciences Inc.

SGMT

$8.74 ▲ +0.08 (+0.98%) at close

5 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Sagimet Biosciences Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $282.7M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -40.4% ↘

FCF / Share $-1.41 ↘

Trailing P/E —

Price / Book 2.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-51.04M

↓ -12.0% —

FCF / Share Free cash flow per share

$-1.41

↓ -4.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	-9.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	45.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	98.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-12.0% Weak ↑ Weak Improving Year-over-year change in net income	-63.5% Weak Weak Year-over-year change in net income	8.6% Fair Fair Year-over-year change in net income	—	—
FCF Growth YoY (%)	-4.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	40.4% Excellent Excellent Year-over-year change in free cash flow	98.3% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
FCF / Net Income (x)	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-40.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	13.1% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-48.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-94.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-45.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-405%)	-29.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-295%)	-30.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-304%)	16.3% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+9%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Net Debt (USD)	$-35.02M	$-75.84M	$-75.14M	$-158.00K	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	—	—	$0.19	—	—
Basic EPS, GAAP (USD)	$-1.58	$-1.45	$-2.66	$-165.20	—
Free Cash Flow per Share (USD)	$-1.41	$-1.35	$-2.27	$-132.65	—
Book Value per Share (USD)	$3.44	$4.97	$8.71	$-1.01K	—
Tangible Book Value per Share (USD)	$3.44	$4.97	$8.71	$-1.01K	—
Basic Weighted Avg Shares (shares)	32.35M	31.35M	10.46M	184,619	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$111.30M	$148.32M	$90.99M	$27.51M	—
Total Equity (USD)	$111.38M	$155.81M	$91.06M	$-186.95M	$-158.26M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	$2.00M	—	—
Net Income, GAAP (USD)	$-51.04M	$-45.57M	$-27.88M	$-30.50M	—
Operating Cash Flow (USD)	$-45.65M	$-42.44M	$-23.77M	$-24.49M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters

Sagimet Biosciences Inc.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare SGMT with peers